Sequential Nephron Blockade

Visual reference

Browse the visual reference library · Download lesson Markdown

Quick Navigation

Executive Summary

1. Introduction and Clinical Rationale

Diuretic therapy is the cornerstone of volume management in heart failure, nephrotic syndrome, hepatic cirrhosis, and chronic kidney disease. Despite being available since the 1960s, loop diuretics are used in isolation in the majority of hospitalized patients despite compelling mechanistic and emerging clinical data supporting multi-agent sequential nephron blockade (SNB). The consequence of this single-agent paradigm is startling: after 72 hours of intravenous loop diuretic therapy, approximately 85% of ADHF patients still exhibit clinical signs of congestion, and 24% experience treatment failure defined as persistent or worsening fluid overload.

SNB is built on the recognition that the nephron does not passively accept loop-diuretic–induced natriuresis. Instead, it responds with coordinated adaptive compensatory mechanisms across multiple tubular segments that offset sodium losses and perpetuate volume overload:

• The proximal tubule upregulates sodium-hydrogen exchanger 3 (NHE3) in response to reduced effective arterial blood volume (EABV)
• The distal convoluted tubule undergoes structural hypertrophy in response to chronic loop diuretic exposure
• The aldosterone-sensitive distal nephron increases ENaC-mediated reabsorption in response to elevated aldosterone

Each of these maladaptive responses is a pharmacologically reversible target.

2. The Nephron as a Segmental Architecture: Targets and Diuretic Classes

Understanding SNB requires a working map of nephron segment function and diuretic site of action. Sodium reabsorption is distributed across five main functional compartments with quantifiably different contributions to total filtered-load recapture.

2.1 Proximal Convoluted and Straight Tubule (PCT/PST): ~60–67% of Filtered Sodium

The PCT reabsorbs the largest share of filtered sodium, primarily via luminal carbonic anhydrase–mediated NaHCO₃ cotransport (NHE3) and SGLT2-coupled glucose-sodium uptake in the S1/S2 segments. Despite handling the majority of filtered sodium, the PCT is paradoxically the least efficient diuretic target in isolation: any sodium escaping the PCT is largely recaptured downstream.

Agents targeting this segment:

• Acetazolamide (carbonic anhydrase inhibitor): Blocks NaHCO₃ reabsorption at the luminal carbonic anhydrase. Alone, its effect is modest (~5–8% net FENa increase) due to downstream compensation. As an add-on to loop diuretics, it prevents proximal tubular sodium hyperreabsorption that drives diuretic resistance in states of reduced EABV.
• SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): Block SGLT2 in the S1/S2 proximal tubule, inhibiting glucose-coupled sodium reabsorption. Downstream compensatory mechanisms rapidly and nearly completely offset the natriuretic effect within days. The net result is a short-lived, water-predominant diuresis rather than a sustained natriuresis.
• Intravenous sodium bicarbonate: Functions similarly to acetazolamide by delivering a bicarbonate-rich fluid that alkalinizes tubular fluid, partially reversing the metabolic alkalosis that blunts loop diuretic response.

2.2 Thick Ascending Limb of Henle (TAL): ~20–25% of Filtered Sodium

The TAL is the primary target of loop diuretics, which block the Na⁺/K⁺/2Cl⁻ cotransporter (NKCC2). This is the most potent diuretic site per milliequivalent of sodium blocked because the thick ascending limb is impermeable to water. Loop diuretics are correctly described as "high-ceiling" agents.

Agents targeting this segment:

• Furosemide: Bioavailability is erratic (10–90% oral), protein-bound (~96%), secreted via OAT1/3 into the proximal tubule lumen. Half-life ~2 hours in HF.
• Torsemide: Oral bioavailability >80–90%, hepatically cleared, half-life ~6 hours. More predictable pharmacokinetics than furosemide.
• Bumetanide: Bioavailability ~80%, short-acting. Potency ~40:1 vs. furosemide on molar basis.
• Ethacrynic acid: Only non-sulfonamide loop diuretic; reserved for sulfa allergy.

2.3 Distal Convoluted Tubule (DCT): ~5–10% of Filtered Sodium

The DCT reabsorbs sodium via the Na⁺/Cl⁻ cotransporter (NCC). Loop diuretic–induced chronic sodium delivery to the DCT drives compensatory NCC upregulation and tubular hypertrophy — the anatomical substrate for the "post-diuretic braking phenomenon."

Agents targeting this segment:

• Hydrochlorothiazide (HCTZ): Bioavailability ~60–80%. Effective at GFR >30 mL/min; loses efficacy at lower GFR.
• Metolazone: Retains efficacy at GFR as low as 10–15 mL/min. Excellent first choice for SNB in CKD.
• Chlorothiazide: The only IV thiazide available (500–1000 mg IV); useful for patients with bowel edema.
• Indapamide: Thiazide-like with modest vasodilatory properties.

2.4 Aldosterone-Sensitive Distal Nephron (ASDN): ~2–3% of Filtered Sodium

The ASDN — comprising the late DCT, connecting tubule, and cortical/medullary collecting duct — mediates sodium reabsorption via the epithelial sodium channel (ENaC), regulated primarily by aldosterone.

Agents targeting this segment:

• Spironolactone: MRA. Anti-fibrotic and cardioprotective properties.
• Eplerenone: Selective MRA; less gynecomastia. Preferred in males.
• Amiloride: Direct ENaC blocker; more rapid onset than MRAs (hours vs. days).
• Triamterene: ENaC blocker; shorter duration than amiloride.
• Finerenone: Non-steroidal MRA; currently indicated in CKD with diabetes.

2.5 Inner Medullary Collecting Duct: Vasopressin-Regulated Water Channels

Aquaporin-2 (AQP2) channels mediate vasopressin-regulated free water reabsorption. This segment is the target of vaptans.

Agents targeting this segment:

• Tolvaptan: Selective V2 receptor antagonist; produces purely aquaretic (water without sodium) diuresis. Its role in SNB is niche but mechanistically distinct from all other agents.

3. Diuretic Effectiveness: Segment-by-Segment Baseline

Before building the combination matrix, it is necessary to establish individual agent effectiveness. "Effectiveness" refers to net 24-hour natriuresis relative to a hypothetical untreated baseline (FENa typically <0.35% in edematous states with reduced EABV).

Note: Loop diuretic response (4–6× baseline) is the reference standard. All combination multipliers below are expressed relative to loop diuretic monotherapy.

4. Sequential Combination Effectiveness: Building the Nephron Blockade Matrix

4.1 The Conceptual Framework

Knauf and Mutschler established the theoretical and clinical foundations of SNB, demonstrating that the major mechanism of resistance was excessive proximal tubular sodium reabsorption, addressable by coadministering carbonic anhydrase inhibitors. The principle: low-dose combination therapy targeting multiple segments is more effective and safer than high-dose monotherapy.

4.2 Two-Agent Combinations (Loop Diuretic as Backbone)

Combination 1: Loop + Thiazide/Metolazone (DCT Blockade)

This is the best-studied SNB combination. Loop diuretics deliver a heightened sodium load to the DCT; DCT hypertrophy creates a compensatory "distal sodium conservation" loop. Thiazide blockade intercepts this compensation directly.

Combination 2: Loop + Acetazolamide (Proximal Blockade)

The ADVOR trial (n=519) is the only large RCT of proximal SNB. IV acetazolamide 500 mg daily added to standardized IV loop diuretics achieved successful decongestion in 42.2% vs. 30.5% (RR 1.46, 95% CI 1.17–1.82; p<0.001). Patients with baseline HCO₃ ≥27 mmol/L showed greater benefit (OR 2.39).

Combination 3: Loop + Potassium-Sparing Diuretic (ASDN Blockade)

K-sparing agents add modest incremental natriuresis but serve critical roles in electrolyte preservation, aldosterone antagonism, and anti-fibrosis. In the PHARES trial, SNB with furosemide + spironolactone + amiloride produced markedly greater blood pressure reduction than combined RAAS blockade in resistant hypertension.

Combination 4: Loop + SGLT2 Inhibitor (Proximal Osmotic Blockade)

SGLT2 inhibition produces glucosuria with complex sodium and water responses. EMPULSE met a hierarchical composite endpoint incorporating death, HF events and symptoms in clinically stable hospitalized patients; it was not designed to establish an isolated mortality reduction. These agents complement, rather than replace, loop-based decongestion. EMPULSE; renal physiology review.

5. Three-Agent, Four-Agent, and Five-Agent Combination Matrices

5.1 Conceptual Ceiling and Diminishing Returns

As additional nephron segments are blocked, there are two countervailing forces: (1) incrementally greater net natriuresis as compensatory reabsorption is disabled; and (2) diminishing marginal returns because each additional segment contributes less filtered sodium. Importantly, full nephron blockade shifts urine composition toward a plasma-like isotonic solution — this is the physiologic rationale for SNB safety as well as efficacy.

5.2 Three-Agent Combinations

Regimen A: Loop + Acetazolamide + Thiazide (PCT + TAL + DCT)

This combination targets three sequential segments and is arguably the most rational escalation from the ADVOR framework. Estimated relative effectiveness: ~3–5× loop alone.

Regimen B: Loop + Thiazide + Potassium-Sparing

The most commonly employed practical triple regimen. The MRA or amiloride is essential for electrolyte preservation. Estimated effectiveness: ~2.5–4× loop alone.

5.3 Four-Agent Combinations

Four-agent SNB is the domain of the advanced heart failure inpatient unit or the cardiorenal ICU, implying blockade of four distinct nephron segments.

5.4 Five-Agent Combination (Total Nephron Blockade)

Five-agent SNB represents the closest achievable approximation to total nephron blockade.

6. Hypertonic Fluids in Decongestive Therapy

6.1 Hypertonic Saline (3% NaCl)

Hypertonic saline (HS) concurrently with high-dose loop diuretics counteracts the paradox of the volume-overloaded patient with reduced EABV. The mechanism: bolus HS mobilizes fluid from interstitial to intravascular compartment through osmotic forces, restoring renal perfusion and improving diuretic delivery.

A 2014 meta-analysis (n=1,032) demonstrated a 44% reduction in all-cause mortality (RR 0.56, 95% CI 0.41–0.76; p=0.0003) and a 50% reduction in HF rehospitalization (RR 0.50, 95% CI 0.33–0.76; p=0.001).

HS functions not as a direct nephron-segment blocker but as a pharmacokinetic enhancer of loop diuretics — a "Segment 0" intervention that potentiates all subsequently administered agents.

Estimated contribution: ~2–3× urine output vs. loop alone in diuretic-resistant patients.

6.2 Intravenous Sodium Bicarbonate

Metabolic alkalosis is a frequently underrecognized co-conspirator in diuretic resistance. Alkalosis drives proximal tubular NaHCO₃ reabsorption, creating a cycle: alkalosis → increased proximal Na reabsorption → more renal Na retention → more alkalosis.

IV sodium bicarbonate serves two roles in SNB:

1. Direct alkalinization of tubular fluid: Partially mimics acetazolamide's mechanism.
2. Intravascular volume expansion: Improves renal perfusion and enhances loop diuretic delivery.

Clinical indication: Serum HCO₃ >30 mEq/L with diuretic resistance. Protocol: 150 mEq in 1L D5W at 1–2 mL/kg/hr. Estimated diuretic contribution: ~1.1–1.3× loop alone.

7. Furosemide Drip vs. Increasing Segments Blocked

7.1 DOSE Trial Evidence

The DOSE trial (Felker et al., NEJM 2011) randomized 308 ADHF patients in a 2×2 factorial design. Results:

• Bolus vs. continuous infusion: No significant difference in symptom assessment (p=0.47), creatinine change, net volume loss (4237 vs. 4249 mL), mortality, length of stay, or treatment failure.
• Low-dose vs. high-dose: High-dose (2.5× home dose) showed greater net fluid loss, weight loss, and dyspnea relief but no significant primary endpoint difference.

7.2 The Critical Comparison: Drip vs. SNB

The fundamental limitation of escalating furosemide drip rate is that loop diuretics act on only one segment (TAL, ~25% of filtered Na). At the ceiling dose, every additional milligram is wasted. SNB disassembles the compensatory architecture itself.

8. Oral vs. Intravenous Diuretics

8.1 The Pharmacokinetic Problem with Oral Furosemide

Oral furosemide bioavailability ranges from 10% to 90%, with an average of ~50% in euvolemic patients but substantially less in decompensated heart failure due to bowel wall edema. Because loop diuretics require a minimum plasma concentration threshold to trigger natriuresis, slow and erratic absorption may mean the drug never crosses this threshold despite adequate dosing.

8.2 Torsemide as the Superior Oral Loop Diuretic

Torsemide is the pharmacokinetically rational oral loop diuretic: bioavailability 80–100%, half-life ~6 hours, absorption unaffected by bowel edema, and IV-to-oral equivalency of 1:1. A meta-analysis (n=19,280) demonstrated significantly greater functional class improvement (NNT=5) and fewer HF hospitalizations (10.6% vs. 18.4%; OR 0.72).

8.3 Comparative Effectiveness Table

8.4 The Outpatient Decongestion Dilemma

The transition from inpatient IV to outpatient oral diuretics is a critical failure point. Patients discharged on oral furosemide at the same milligram dose will receive approximately half the effective drug dose in bioavailability-equivalent terms.

Practical strategies:

1. Discharge on torsemide rather than furosemide, or double the furosemide dose at discharge.
2. Add metolazone 2.5–5 mg PO 2–3 times weekly to an established oral loop diuretic in patients with recurrent decompensation.
3. Pre-emptive "congestion action plans" with daily weight monitoring and standing metolazone order for weight gain ≥2 lbs/24h or ≥5 lbs/7 days.
4. Consider ambulatory infusion center IV diuresis for patients with recurrent ADHF from bowel edema–impaired absorption.

9. Special Considerations: Nephrology-Specific Applications

9.1 CKD and Advanced Kidney Disease

Loop diuretic efficacy is progressively impaired in CKD. CKD patients with GFR <30 mL/min may require furosemide doses of 200–400 mg IV to achieve the same response as 40 mg IV in normal kidney function. Metolazone retains efficacy at GFR as low as 10–15 mL/min, making it the thiazide of choice for SNB in advanced CKD.

9.2 Nephrotic Syndrome

Nephrotic syndrome creates a unique pharmacokinetic barrier: intraluminal protein binds furosemide in the tubular lumen, reducing the free (pharmacologically active) fraction. Loop + thiazide SNB remains effective and is the preferred escalation strategy.

9.3 Cardiorenal Syndrome Types 1 and 2

CRS Type 1 (acute HF causing AKI) and Type 2 (chronic HF causing CKD) are settings where aggressive decongestion improves renal outcomes despite transient creatinine rise — the "azotemia-decongestion paradox." SNB is appropriate even when creatinine rises modestly (≤0.3–0.5 mg/dL from baseline).

9.4 Transplant Considerations

Post-transplant patients on calcineurin inhibitors are particularly susceptible to hyperkalemia with K-sparing agents. Amiloride is preferred over spironolactone due to more predictable potassium kinetics. Acetazolamide is useful in post-transplant metabolic alkalosis.

10. Summary Algorithm and Key Clinical Pearls

10.1 Step-Up Framework for Refractory Congestion

10.2 Key Clinical Pearls Summary

11. IV Furosemide Bolus vs. Furosemide Drip: The Evidence-Based Comparison

11.1 The Theoretical Rationale for the Drip (and Why It Was Wrong)

The case rested on two pharmacokinetic arguments: (1) maintaining plasma levels above the natriuretic threshold continuously, and (2) avoiding high-concentration bolus-driven neurohormonal activation surges. Both arguments are physiologically coherent. The problem is they did not survive clinical testing.

11.2 What the DOSE Trial Actually Showed

The DOSE trial (Felker et al., NEJM 2011; PMID 21366472): 308 patients, 2×2 factorial, 26 centers.

• Symptom VAS AUC: bolus 4236 ± 1440 vs. infusion 4373 ± 1404. P=0.47. No difference.
• Creatinine change at 72h: +0.05 vs. +0.07 mg/dL. P=0.45. No difference.
• Net volume loss at 72h: 4237 mL vs. 4249 mL — a difference of 12 mL over three days.
• Meta-analysis (Ng & Yap, 2018, 8 RCTs, n=669): Continuous infusion gave +461 mL/24h and +0.70 kg weight loss but no difference in mortality, length of stay, or electrolyte disturbance.

11.3 The High-Dose Finding

High-dose (2.5× home oral dose) produced greater net fluid loss, weight loss, more dyspnea relief, and a trend toward better symptom score (p=0.06). Practical translation: when a patient is not responding, the correct first move is to increase the IV dose — not switch to an infusion at the same dose.

11.4 Summary Comparison Table

11.5 High-Rate Infusion at 40 mg/hr

A critical distinction: the DOSE trial did not test 40 mg/hour infusions. The high-dose arm delivered roughly 200 mg IV/day — approximately 8 mg/hour. The conclusion "drip is equivalent to bolus" applies to 6–8 mg/hour, not 40 mg/hour.

When a patient fails at 10–20 mg/hour and responds promptly to 40 mg/hour, this is a dose-threshold phenomenon, not a route effect. The drip at 40 mg/hour is a vehicle for delivering a substantially higher total dose per unit time.

12. Furosemide Drip + Sequential Nephron Blockade: The Complete Comparison Table

12.1–12.2 The Additive-With-Compensation Principle

When the loop diuretic blocks the TAL, the nephron activates compensatory reabsorption at the DCT and ASDN. In a healthy person, this compensation is appropriate. In the volume-overloaded patient, it is the mechanism of diuretic resistance. When a thiazide blocks the DCT, it allows the full upstream natriuretic effect of the loop diuretic to manifest. The net result is substantially greater than the DCT's baseline 5–10% segment contribution would suggest, because it is freeing the loop diuretic's effect from its primary compensatory constraint.

12.3 The Full Comparison Table

12.4 Reading the Table

13. Evidentiary Framework

13.1 Tier 1 — Direct RCT and Meta-Analysis Evidence

• Loop diuretic alone (1.0×): DOSE trial. Net 72-hour volume loss ~4,200–4,250 mL. After 72h, 85% still congested, 24% had persistent/worsening HF.
• Loop + acetazolamide (~1.46×): ADVOR primary endpoint. RR 1.46 (95% CI 1.17–1.82; p<0.001). HCO₃ ≥27 subgroup: OR 2.39.
• Hypertonic saline (~2–3×): Gandhi 2014 meta-analysis (n=1,032). 44% mortality reduction, 50% rehospitalization reduction.

13.2 Tier 2 — Physiologic Derivation + Indirect Evidence

• Segmental sodium contributions: Established renal physiology (micropuncture/clearance studies). Knauf and Mutschler cross-referenced with measured FENa responses.
• Loop + thiazide (~2–4×): 2023 systematic review pooling multiple retrospective and prospective studies.

13.3 Tier 3 — Mechanistic Extrapolation

The 3-, 4-, and 5-agent multipliers are constructed by applying the additive-with-compensation principle iteratively from Tier 1 and Tier 2 anchors. They are not invented; they are derived. But they have not been directly measured in a controlled trial.

14. Interpreting Urine Sodium During Decongestion

14.1 Measure response in context

Early urine sodium and urine output can help assess response to an IV loop diuretic in acute heart failure. ESC guidance describes a spot sample around two hours after dosing as one part of reassessment. Interpret concentration alongside urine volume, dose, timing, congestion, blood pressure, kidney function and electrolyte trends. ESC guidance.

14.2 A concentration does not localize the nephron segment

A low urine sodium suggests limited sodium excretion in context, but cannot quantify proximal reabsorption, diagnose NHE3 or NCC upregulation, or select acetazolamide versus a thiazide by itself. A high value does not independently diagnose tubular injury or exclude a low total sodium output. Diuretics, GFR, water handling and collection timing affect the result.

14.3 Reassess before escalation

Serial urine-sodium studies and DIURESIS-AHF describe associations with decongestion and prognosis. They do not validate a rigid urine-sodium map of tubular transport or an automatic drug-selection algorithm. Serial measurements; DIURESIS-AHF.

15. Loop Diuretics, the Furosemide Stress Test and LIBERATE-D

15.1 Distinguish volume treatment from kidney recovery

Loop diuretics can help manage fluid overload in AKI when a diuretic response remains. They do not reverse tubular injury or provide a proven kidney-recovery benefit. Experimental oxygen-demand or cast-clearance mechanisms should not be presented as established clinical cytoprotection. Assess perfusion and volume status before treatment.

15.2 Use the FST as a prognostic test

The furosemide stress test has been studied to estimate progression risk in selected patients with early AKI. A poor response increases concern for severe AKI; a response does not confirm normal tubular viability or guarantee that dialysis will be unnecessary. Use a standardized local protocol with appropriate volume and hemodynamic assessment. Original study; systematic review.

15.3 What LIBERATE-D tested

LIBERATE-D enrolled hemodynamically stable patients who had already started kidney replacement therapy for AKI. It compared dialysis triggered by specified clinical/metabolic indications with conventional scheduled dialysis. Recovery at discharge was 64% versus 50% in the unadjusted comparison; the prespecified adjusted estimate was uncertain and crossed no effect. A larger trial was recommended. Liu et al., JAMA 2026.

The study did not test starting furosemide to prevent initial dialysis, did not validate an FST-selected dialysis-avoidance protocol, and did not prove that withholding indicated dialysis repairs injured kidneys.

15.4 Apply the evidence safely

References

1. Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. 1997;29(3):367-372. PubMed
2. Knauf H, Mutschler E. Low-dose segmental blockade of the nephron rather than high-dose diuretic monotherapy. Eur J Clin Pharmacol. 1993;44(suppl 1):S63-S68. PubMed
3. Wilcox CS, Testani JM, Pitt B. Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure. Hypertension. 2020. PubMed PMID 32829662
4. Mullens W, Dauw J, Martens P, et al.; ADVOR Study Group. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387(13):1185-1195. PubMed
5. Martens P, Dauw J, Verbrugge FH, et al. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial. Circulation. 2023. PubMed.
6. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. PubMed
7. Gandhi S, Mosleh W, Myers RBH. Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis. Int J Cardiol. 2014;173(1):139-145. PubMed
8. Griffin M, Soufer A, Goljo E, et al. Real world use of hypertonic saline in refractory acute decompensated heart failure: a U.S. center's experience. JACC Heart Fail. 2020;8(3):199-208. PubMed
9. Packer M, Wilcox CS, Testani JM. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes. Circulation. 2023. PubMed PMID 37486998
10. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022. PubMed PMID 35228754
11. Rao VS, Cox ZL, Ivey-Miranda JB, et al. Mechanistic Differences between Torsemide and Furosemide. J Am Soc Nephrol. 2025;36(1):99-107. PubMed
12. Abraham B, Megaly M, Sous M, et al. Meta-analysis comparing torsemide versus furosemide in patients with heart failure. Am J Cardiol. 2020;125(1):92-99. PubMed
13. Fouassier D, Blanchard A, Fayol A, et al. Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension. ESC Heart Fail. 2020;7(5):2615-2625. PubMed
14. Ng KT, Yap JLL. Continuous infusion vs. intermittent bolus injection of furosemide in acute decompensated heart failure: systematic review and meta-analysis. Anaesthesia. 2018;73(2):238-247. PubMed
15. Diaz-Arocutipa C, Denegri-Galvan J, Vicent L, et al. The added value of hypertonic saline solution to furosemide monotherapy in patients with acute decompensated heart failure: a meta-analysis and trial sequential analysis. Clin Cardiol. 2023;46(8):853-865. PubMed
16. Biegus J, Zymlinski R, Sokolski M, et al. Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. Eur J Heart Fail. 2019;21(5):624-633. PubMed
17. Collins S, Storrow AB, Albert NM, et al. Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group. J Card Fail. 2015. PubMed PMID 25042620
18. Fujimoto Y, Kitai T, Nasu T, et al. Diuretic resistance measured by sodium excretion and urine output in acute heart failure: The DIURESIS-AHF study. J Cardiol. 2026;87(2):167-173. DOI | PubMed
19. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. PubMed
20. Fujimoto Y, Kitai T, Nasu T, et al. The dynamics of urine sodium concentration after intra-venous furosemide in patients with acute heart failure. Eur Heart J. 2024;45(Suppl 1):ehae666.1181. Conference abstract (not a full PubMed-indexed article).
21. Bagshaw SM, Delaney A, Haase M, Ghali WA, Bellomo R. Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Crit Care Resusc. 2007;9(1):60-68. PubMed
22. Ho KM, Sheridan DJ. Meta-analysis of furosemide to prevent or treat acute renal failure. BMJ. 2006;333(7565):420. PubMed
23. Chen JJ, Chang CH, Huang YT, Kuo G. Furosemide stress test as a predictive marker of acute kidney injury progression or renal replacement therapy: a systematic review and meta-analysis. Crit Care. 2020;24(1):202. PubMed
24. Chawla LS, Davison DL, Brasha-Mitchell E, et al. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care. 2013;17(5):R207. PubMed
25. Koyner JL, Davison DL, Brasha-Mitchell E, et al. Furosemide stress test and biomarkers for the prediction of AKI severity. J Am Soc Nephrol. 2015;26(8):2023-2031. PubMed
26. Liu KD, Siew ED, Tuot DS, et al. A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury: The Liberation From Acute Dialysis (LIBERATE-D) Randomized Clinical Trial. JAMA. 2026. PubMed PMID 41201895
27. The STARRT-AKI Investigators. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med. 2020;383(3):240-251. PubMed

This review was prepared for clinical education purposes. Not intended as a substitute for individualized clinical judgment.

Andrew Bland, MD, FACP, FAAP